How to Get a GLP-1 Prescription

Getting a GLP-1 medication for weight loss sounds simple until you try. Friends say they got a pen from “an online clinic.” Ads promise a prescription in hours. Your insurance portal says “prior authorization required.” And somewhere in the mix you still need a real clinician who knows your history.

The process is more straightforward than the noise suggests. In the United States these medicines are prescription-only. A licensed clinician has to decide they are appropriate for you, write the script, and send it to a pharmacy that is allowed to fill it. This guide walks through how that works in practice: who can prescribe, what the labels and guidelines say about who is a candidate, how primary care, specialty and telehealth paths differ, what to bring to the visit, how insurance and compounded products fit in, and which FDA warning signs mean you should walk away.

Educational only. This article is not medical advice and not an endorsement of any clinic, pharmacy or program. Whether a GLP-1 is right for you is a decision to make with a licensed clinician who knows your full health history. Do not start, stop or change any medicine based on an article alone.

The short answer

To get a GLP-1 prescription for weight loss in the US:

1. Confirm you may be a candidate. FDA-approved weight-management products such as Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated, with a reduced-calorie diet and more physical activity, for adults with obesity or adults with overweight plus at least one weight-related condition. In everyday clinical language that usually means a BMI of 30 or higher, or 27 or higher with a related condition.
2. See a licensed clinician. Start with primary care, an obesity-medicine or other specialist, or a legitimate telehealth program. Yale Medicine’s obesity specialists emphasize follow-up over a one-time script.
3. Complete a real evaluation. Expect a review of your history, medications, contraindications and goals. Some programs also order baseline labs.
4. If appropriate, get a prescription filled by a state-licensed pharmacy. Prefer FDA-approved products when they meet your needs. FDA says compounded versions should only be used when an approved drug cannot.
5. Plan for cost and follow-up. Insurance may need prior authorization. Side effects, dose changes and long-term use all need ongoing clinician contact.

That is the whole pathway. Everything below fills in the details.

Who can write the prescription?

Yale Medicine is direct on this point: any licensed health care provider with prescribing authority can prescribe GLP-1 medications when they are appropriate. That list includes:

• primary care physicians,
• nurse practitioners and physician assistants (within state rules),
• endocrinologists, cardiologists, gastroenterologists and other specialists,
• clinicians who are board-certified in obesity medicine.

What Yale’s experts stress is not the specialty title on the door. It is whether the clinician treats obesity as a chronic disease and can stay with you. John Morton, MD, MPH, chief of Bariatric and Minimally Invasive Surgery at Yale Medicine, notes that about half of patients who start a GLP-1 stop within a year, often because of side effects, cost or lack of follow-up. “You don’t want to get a prescription and walk away,” he says in the Yale explainer. Continuity of care is part of getting the prescription right, not an optional extra.

On X and in everyday conversation, people still ask how to “get their hands on” Ozempic or Wegovy as if it were an over-the-counter product. It is not. Even posts that try to be helpful usually land on the same rule: a licensed prescriber has to review your health history first. That matches FDA guidance and clinical practice.

Do you meet the medical criteria?

Before you book anything, it helps to know what labels and federal agencies actually say. A fuller walkthrough lives in our guide to who qualifies for GLP-1 weight-loss treatment; here is the short version.

What the labels say

The Wegovy prescribing information states that the medicine is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and adolescents 12 and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It has additional approved uses for lowering major cardiovascular events in adults with established heart disease and obesity or overweight, and for certain adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis.

Yale Medicine summarizes the everyday clinical thresholds for GLP-1 weight-loss drugs as:

• BMI of 30 or higher, or
• BMI of at least 27 plus a weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, cardiovascular disease that raises heart-attack or stroke risk, or MASH.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) uses the same BMI cutoffs for who might benefit from prescription weight-management medicines in general: BMI 30 or greater, or BMI 27 or greater with weight-related health problems such as high blood pressure or type 2 diabetes.

CDC’s adult BMI categories define overweight as BMI 25.0 to 29.9 and obesity as 30.0 or greater (with Class 1, 2 and 3 obesity bands above that). BMI is a screening tool, not a diagnosis by itself. Your clinician should also weigh your medical history, exam and labs.

Absolute “no”s you should expect to discuss

Yale Medicine lists groups for whom GLP-1s are generally not recommended: pregnancy (safety data are limited and pregnancy needs appropriate weight gain), a prior history of pancreatitis, and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Labels for Wegovy and related products carry a boxed warning about thyroid C-cell tumors seen in rodents and contraindicate use in people with personal or family MTC or MEN 2 history. Stony Brook Medicine clinicians, in a public educational episode, similarly flag pregnancy, breastfeeding, prior pancreatitis and those thyroid-related contraindications as reasons someone may not be a candidate.

Meeting BMI criteria does not mean you will automatically get a prescription. It means you are in the population the labels were studied and approved for. The clinician still decides.

Three common paths to a prescription

Path 1: Your primary care clinician

For many people this is the best first call. You already have a chart, medication list and relationship. Yale Medicine notes that primary care clinicians are increasingly comfortable prescribing these medicines, and Avlin Imaeda, MD, PhD, a Yale gastroenterologist board-certified in obesity medicine, says what matters most is what is best for the patient.

Pros: history already known; easier coordination with your other conditions; often better for insurance paperwork.

Cons: visits can be short; some primary care clinics have limited time for nutrition coaching or side-effect troubleshooting.

Ask for a dedicated weight-management visit rather than tacking the request onto a rushed sick visit. Bring the materials listed below so the visit can move from “interest” to a clear yes, no or next-step plan.

Path 2: An obesity-medicine or specialty clinic

Obesity-medicine physicians, endocrinology clinics, cardiology and GI programs, and multidisciplinary weight centers exist specifically for this work. Yale’s Center for Weight Management, for example, combines specialists with dietitians, psychologists and exercise physiologists. That kind of team is useful if you have complex medical history, need more support around eating and activity, or have already tried medication without good follow-up.

You do not have to start here. Many people begin in primary care and get referred later if needed.

Path 3: Legitimate telehealth

Telehealth is now a mainstream route. The US Department of Health and Human Services explains on Telehealth.HHS.gov that telehealth lets you talk with a provider by phone or video, send secure messages, and share tracked health data such as blood pressure, without going to an office. Benefits include less travel, potentially faster appointments and access to clinicians who are not near you. HHS also notes that telehealth is not right for every person or every condition, and you may still need in-person care sometimes.

A careful online program typically:

• collects a detailed health questionnaire,
• has a licensed clinician review your case (ideally with real-time video or phone, not only a form),
• screens for contraindications,
• may order or request labs,
• writes a prescription only if appropriate, and
• fills it through a state-licensed pharmacy, often with scheduled follow-up.

Our deeper guide to how telehealth weight-loss programs work covers the intake-to-shipping flow and FDA red flags in more detail. For choosing among programs, start from the Telehealth Weight Loss hub rather than chasing every ad.

In 2026 reporting, U.S. News Health editor Gretel Schueller warned Scripps News viewers about platforms that email a prescription within hours after a questionnaire with no clinician interaction, and about services that skip medical-history review or baseline blood work. Her practical checklist matches FDA themes: keep your primary care clinician informed, insist on real-time clinician contact when possible, and confirm that history and labs are part of the process.

What happens at the visit (and what to bring)

Whether the visit is in a clinic or on video, a serious evaluation covers more than your weight today.

Expect the clinician to review:

• height, weight and BMI,
• weight-related conditions and past weight-loss attempts,
• personal and family history relevant to contraindications (including thyroid cancer syndromes and pancreatitis),
• current medicines and supplements,
• pregnancy plans or breastfeeding,
• mental health and eating-pattern concerns when relevant,
• your goals and ability to combine medication with diet and activity changes.

NIDDK is clear that prescription weight-management medicines are meant to support healthy eating and physical activity, not replace them. Labels for Wegovy and related products say the same: use with a reduced-calorie diet and increased physical activity.

Bring or have ready:

• a full medication and supplement list (including anything bought online),
• recent labs if you have them (A1C, lipids, kidney and liver tests are commonly useful),
• blood pressure readings if you track them,
• your insurance card and pharmacy preference,
• notes on side effects you worry about (nausea is the one people ask about most; see our GLP-1 nausea guide),
• a short written question list: follow-up schedule, what to do if you feel sick, how long treatment usually continues, and what your out-of-pocket cost will be.

If the answer is yes, many clinicians start at the lowest dose and escalate slowly. Yale’s Dr. Imaeda describes increasing at most about once a month when side effects are manageable. Exact schedules belong on the product label and with your prescriber; this article does not give personal dosing advice.

If the answer is not yet, ask what would need to change: more documentation for insurance, treatment of another condition first, or a different medicine. A thoughtful “not right now” is still a successful visit.

After the prescription: pharmacy, insurance and cost

Where the medicine comes from

FDA tells patients to obtain a prescription from their doctor and fill it at a state-licensed pharmacy. For online purchases, BeSafeRx lists safe signs: the pharmacy always requires a doctor’s prescription, provides a US physical address and phone number, has a licensed pharmacist available, and is licensed by a state board of pharmacy. Warning signs include no prescription requirement, no US license, no pharmacist to answer questions, damaged or unlabeled packaging, and prices that seem too good to be true.

Prior authorization and coverage

Many insurers treat GLP-1 weight-loss drugs as specialty benefits. Expect paperwork that documents BMI, comorbidities and sometimes prior lifestyle attempts. Clinics and some telehealth programs submit prior authorizations for you; others ask you to chase the insurer yourself. Ask who owns that step before you pay program fees.

NIDDK notes that some insurance plans cover these medicines and some do not, and recommends contacting your insurer. For people on Medicare with Part D, Medicare.gov describes a temporary GLP-1 Bridge program beginning July 1, 2026, covering certain products (including listed Wegovy and Zepbound forms and Foundayo) for eligible adults, with stricter BMI and condition rules than the FDA labels and a $50 monthly copay when you qualify. Your clinician must send the prescription and complete prior authorization when asked, and certify that you are using the medicine as part of a lifestyle program focused on diet and exercise. Eligibility details and exclusions are on Medicare.gov; they are not the same as “anyone who meets the FDA label.”

Cash-pay options and manufacturer programs change often. For a sense of sticker prices without insurance, see our explainer on semaglutide cost without insurance and the broader Costs Without Insurance hub.

FDA-approved brand vs compounded product

This is the decision that generates the most confusion online.

• FDA-approved products (for example Wegovy for chronic weight management, Zepbound for weight management and certain sleep apnea indications, and other labeled options summarized in our FDA-approved GLP-1s guide) have been reviewed by FDA for safety, effectiveness and quality for their labeled uses.
• Compounded semaglutide or tirzepatide is not FDA-approved. FDA’s page on unapproved GLP-1s used for weight loss (current as of October 1, 2026) states that unapproved versions do not undergo FDA review for safety, effectiveness and quality before marketing, and that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. FDA also tells patients to use BeSafeRx resources when buying online and to talk with their doctor about their medicines.

Separately, FDA has warned telehealth companies against promoting compounded drugs with false or misleading claims, including describing a compounded drug as generic, FDA-approved, clinically proven to match an approved drug, or sourced from an “FDA-approved pharmacy” (FDA does not approve or license pharmacies that way). Content on that page was current as of June 15, 2026.

If a seller markets a compounded vial as “the same as” a brand pen, that is a red flag, not a bargain description.

Red flags: when to stop and look elsewhere

Combine FDA’s telehealth red flags, BeSafeRx pharmacy warnings and common-sense clinical standards. Walk away or get a second opinion if a seller:

• does not require screening and a prescription by a licensed clinician,
• has no clinician available after you receive the medicine,
• claims a compounded drug is the same as, generic equivalent of, or FDA-approved like a brand product,
• offers prices that seem too good to be true,
• ships medicine that looks different than expected, arrives damaged, lacks instructions, or comes warm when it should have been refrigerated (FDA advises not using injectable GLP-1 products that arrive warm or poorly refrigerated),
• uses an online pharmacy with no US address, no phone number, or no licensed pharmacist,
• pressures you to buy before answering basic safety questions.

Public posts from clinicians occasionally describe patients who received injectables from someone who was not the prescribing clinician, with unclear sourcing. Those stories are anecdotes, not studies, but they rhyme with FDA’s insistence on a clear prescriber–pharmacy chain. If you cannot answer “who prescribed this, which pharmacy made or dispensed it, and who do I call if I have a reaction?”, do not use it.

Also tell your regular doctor if you start a GLP-1 through any channel. Your primary medication list needs to stay complete.

Questions worth asking before you leave the visit

You do not need a perfect script. A few clear questions prevent most surprises:

1. Am I a candidate under the label, and why or why not?
2. Which product are you prescribing, and is it an FDA-approved brand or a compounded formulation?
3. Which pharmacy will fill it, and how do I confirm it is state-licensed?
4. Who handles prior authorization, and what will I pay if insurance denies?
5. How will we follow up on side effects and dose changes?
6. What should I do about protein, strength training and nausea in the first months?
7. If I want to stop later, how should we plan that together?

For a longer checklist on the eligibility side, see who qualifies. For the wider GLP-1 learning path, start at the GLP-1 Guide hub.

Bottom line

Getting a GLP-1 prescription is a medical process, not a checkout flow. A licensed clinician reviews whether you fit the label criteria, screens for reasons not to treat, and, if appropriate, sends a prescription to a state-licensed pharmacy. Primary care, specialty obesity care and legitimate telehealth can all work when follow-up is real. Insurance and cost often take as much planning as the clinical decision. Prefer FDA-approved products when they meet your needs, treat compounded versions with the caution FDA asks for, and treat any seller who skips a clinician or claims a compounded drug is “the same as” a brand product as a hard no.

If you are ready for the next step, book a visit with a clinician you trust, bring your history and questions, and decide together whether a GLP-1 belongs in your plan.